Gritstone bio, Inc., a clinical-stage biotechnology company, engages in developing vaccine-based immunotherapy candidates against cancer and infectious diseases. - Headquarters: Emeryville, California
- Founded: August 2015
- IPO: September 28, 2018
- The company changed its name to Gritstone bio, Inc. in May 2021.
- Ticker: GRTS
Gritstone bio, Inc. has a strategic collaboration with bluebird bio, Inc.; collaboration agreement with Gilead Sciences, Inc.; and license agreement with Genevant Sciences GmbH.
The company reported on clinical trial outcomes for its cancer vaccine, GRANITE. Although some data were promising, particularly in certain patient subgroups, the overall results were not as compelling as hoped, leading to stock price declines.
On October 10, 2024, Gritstone bio, Inc. filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the District of Delaware.
The company's shares were delisted from Nasdaq following its bankruptcy filing, with trading suspension announced to start on October 22, 2024. The stock symbol transitioned to GRTSQ due to the bankruptcy proceedings.
Oct 18, 24:
